Tyropanoate Sodium

CHEMBL1200899 Phase 4 승인됨 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

663.0 g/mol

LogP

—

Phase

4

Tyropanoate sodium is an iodinated oral cholecystographic contrast agent that is taken up by the liver and concentrated in the bile and gallbladder, making these structures radiopaque for visualization on X-ray imaging. It was used for oral cholecystography to diagnose gallbladder disease and biliary tract disorders. Its iodine content also transiently inhibits thyroid hormone metabolism and was occasionally used to manage hyperthyroidism.

분자량

663.0000 g/mol

TPSA

69.20 Å²

작용 기전

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

2D 구조

SVG PNG

Cite this structure

Embed this structure

SMILES

CCCC(=O)Nc1c(I)cc(I)c(CC(CC)C(=O)[O-])c1I.[Na+]

InChI

InChI=1S/C15H18I3NO3.Na/c1-3-5-12(20)19-14-11(17)7-10(16)9(13(14)18)6-8(4-2)15(21)22;/h7-8H,3-6H2,1-2H3,(H,19,20)(H,21,22);/q;+1/p-1

Molecular Formula

C15H17I3NNaO3

HBD / HBA

1 / 3

회전 가능 결합

7

무거운 원자

23

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

Tyropanoate sodium is an iodinated oral cholecystographic contrast agent that is taken up by the liver and concentrated in the bile and gallbladder, making these structures radiopaque for visualization on X-ray imaging. It was used for oral cholecystography to diagnose gallbladder disease and biliary tract disorders. Its iodine content also transiently inhibits thyroid hormone metabolism and was occasionally used to manage hyperthyroidism.

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Yes, Tyropanoate Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200899. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 541384. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

환자 친화적 정보를 찾고 계신가요?

Tyropanoate Sodium PillFYI에서

구조

핵심 데이터

분자식: C15H17I3NNaO3

외부 링크

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Tyropanoate Sodium

작용 기전

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D 구조

Cite this structure

Embed this structure

No targets recorded

No interactions recorded

No side effects recorded

자주 묻는 질문

References & Data Sources

Embed This Widget